burns%20-%20initial%20management
BURNS - INITIAL MANAGEMENT
Thermal burns are burns due to external heat sources that raises skin and tissue temperature causing tissue cell death or charring. Flame is the most common type of burn. Inhalation injury is found in 30% of victims of major flame burns.
Chemical burns are due to strong acids, alkalis, detergents or solvents coming into contact with the skin. Tissues are damaged by protein coagulation or liquefaction rather than hyperthermic activity.
Electrical burns are due to electrical current or lightning coming in contact with the body.
First degree burns or superficial burns appears similar to sunburn that is painful, dry, swollen, erythematous without blisters and involves only the epidermis.
Second degree burns or partial-thickness burns has appearance of moist blebs, formation of vesicle and blister; underlying tissue is mottled pink and white with good capillary refill; this involves the entire epidermis and a variable portion of the dermal layer.
Third degree burns or full-thickness burns appears dry, leathery eschar, mixed white waxy, khaki, mahogany and soot stained. It involves the entire epidermis and dermis, leaving no residual epidermis cells, may include fat, subcutaneous tissue, fascia, muscle and bone.
Content not found!
Editor's Recommendations
Most Read Articles
Tristan Manalac, 25 Sep 2019
Aqueous cream moisturizers that do not contain sodium lauryl sulphate (SLS) are less irritating to the skin than SLS-containing ones, while achieving similar levels of hydration and skin barrier integrity, according to a recent Singapore study.
Tristan Manalac, 16 Jul 2019
Caffeinated drinks, such as coffee and black tea, may protect against nonmelanoma skin cancer (NMSC) among Chinese in Singapore, according to a recent study.
24 Sep 2019
Generalized and localized dry skin is prevalent among middle-aged and elderly adults, a recent study has found.
5 days ago
New drug applications approved by US FDA as of 01 - 15 October 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.